儿童期起病狼疮性肾炎患儿及青少年的肾脏复发:一项20年研究
该回顾性队列研究纳入2001至2021年诊断的95例中国儿童期起病狼疮性肾炎患者(91%为增殖性肾炎),随访10.2年(标准差5.9),39例发生70次肾脏复发,1、5、10、20年无复发生存率分别为94.7%、68.3%、50.3%、44.5%。多因素分析显示诊断年龄<13.1岁、AZA维持治疗、12个月时PR或未缓解可预测肾脏复发;复发与晚期慢性肾脏病(3-5期)及终末期肾病、感染、骨质减少和高血压发生率升高相关。结论认为肾脏复发常见,达到完全缓解和使用MMF似乎可降低复发。
要点
- 95例儿童期起病LN患者随访10.2年(标准差5.9),39例发生70次肾脏复发,0.07次/患者年。
- 20年无复发生存率44.5%,1、2、3、4、5、10年分别为94.7%、86.0%、80.1%、71.2%、68.3%、50.3%。
- 诊断年龄<13.1岁、AZA维持、12个月PR或未缓解为肾脏复发的预测因素。
核心结论
- 肾脏复发在儿童期起病狼疮性肾炎中常见,尤其在年轻患者中,并与发病率和死亡率增加相关。
- 达到完全缓解和使用MMF似乎可降低肾脏复发发生率。
研究设计与样本
- 回顾性队列研究,纳入2001至2021年诊断时年龄≤18岁的所有儿童期起病狼疮性肾炎患者,共95例中国患者(91%为增殖性狼疮性肾炎),随访10.2年(标准差5.9)。
主要发现
- 12个月完全缓解/部分缓解率分别为78.9%/7.4%。
- 39例患者共发生70次肾脏复发,复发率0.07次/患者年。
- 无复发生存率在1、2、3、4、5、10、20年分别为94.7%、86.0%、80.1%、71.2%、68.3%、50.3%、44.5%。
- 多因素分析显示,诊断年龄<13.1岁(调整HR 2.59,95%CI 1.27-5.29,P=0.01)、AZA维持治疗(调整HR 2.20,95%CI 1.01-4.79,P=0.05)、12个月时部分缓解(调整HR 3.9,95%CI 1.03-9.19,P=0.01)和未缓解(调整HR 3.08,95%CI 1.35-11.3,P=0.04)可预测肾脏复发。
- 肾脏复发与晚期慢性肾脏病(3-5期)和终末期肾病显著相关(17.9% vs 1.8%,P<0.01);复发患者感染(30.8% vs 10.7%,P=0.02)、骨质减少(38.5% vs 17.9%,P=0.04)和高血压(30.8% vs 7.1%,P<0.01)发生率升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is little data on renal relapse in childhood-onset LN (cLN). We investigate the incidence, predictive factors and outcomes related to renal relapse. METHODS: We conducted a retrospective cohort study of all cLN diagnosed at ≤18 years between 2001-2021 to investigate the incidence and outcomes related to renal relapse. RESULTS: Ninety-five Chinese cLN patients (91% proliferative LN) were included. Induction immunosuppression was prednisolone and CYC [n = 36 (38%)] or MMF [n = 33 (35%)]. Maintenance immunosuppression was prednisolone and MMF [n = 53 (54%)] or AZA [n = 29 (31%)]. The rates of complete remission/partial remission (CR/PR) at 12 months were 78.9%/7.4%. Seventy renal relapses occurred in 39 patients over a follow-up of 10.2 years (s.d. 5.9) (0.07 episode/patient-year). Relapse-free survival was 94.7, 86.0, 80.1, 71.2, 68.3, 50.3 and 44.5% at 1, 2, 3, 4, 5, 10 and 20 years, respectively. Multivariate analysis showed that LN diagnosis <13.1 years [adjusted hazard ratio (HRadj) 2.59 995% CI 1.27, 5.29), P = 0.01], AZA maintenance [HRadj 2.20 (95% CI 1.01, 4.79), P = 0.05], PR [HRadj 3.9 (95% CI 1.03, 9.19), P = 0.01] and non-remission [HRadj 3.08 (95% CI 1.35, 11.3), P = 0.04] at 12 months were predictive of renal relapse. Renal relapse was significantly associated with advanced chronic kidney disease (stages 3-5) and end-stage kidney disease (17.9% vs 1.8%, P < 0.01). Furthermore, patients with renal relapse showed an increased incidence of infections (30.8% vs 10.7%, P = 0.02), osteopenia (38.5% vs 17.9%, P = 0.04) and hypertension (30.8% vs 7.1%, P < 0.01). CONCLUSION: Renal relapse is common among cLN, especially among young patients, and is associated with an increased incidence of morbidity and mortality. Attaining CR and the use of MMF appear to decrease the incidence of renal relapse.
引用
- Chan EY, Yap DY, Wong WH, et al. Renal relapse in children and adolescents with childhood-onset lupus nephritis: a 20-year study. Rheumatology (Oxford). 2024. PMID: 37632777. doi:10.1093/rheumatology/kead447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。